Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8850 | 0.80 | GDA (0.33) | PARP1GDAPDPK1LMNAXDH | |
| SCHEMBL11977311 | 0.80 | GDA (0.33) | PARP1GDAPDPK1LMNAXDH | |
| Xanthine SCHEMBL9443796 | 0.79 | MEN1 (0.34) | PARP1LMNAMEN1KMT2ACSNK2A2 | |
| Xanthine SCHEMBL918381 | 0.79 | MEN1 (0.34) | PARP1LMNAMEN1KMT2ACSNK2A2 | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.79 | GDA (0.48) | GDAPDPK1LMNAXDHUSP2 | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.79 | GDA (0.48) | GDAPDPK1LMNAXDHUSP2 | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.78 | GDA (0.47) | GDAPDPK1LMNAXDHUSP2 | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.78 | GDA (0.47) | GDAPDPK1LMNAXDHUSP2 | |
| SCHEMBL13477906 | 0.77 | GDA (0.32) | GDAPDPK1 | |
| SCHEMBL6545701 | 0.76 | GDA (0.34) | PARP1GDAPDPK1LMNAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098287-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | CHENG-YAO CHEN (TW) | 2026-04-09 | — | — | US | claimed |
| EP-3922266-B1 | TOLL-LIKE RECEPTOR 7 OR 8 AGONIST-CHOLESTEROL COMPLEX, AND USE OF SAME | PROGENEER INC (KR) | 2026-04-08 | — | — | EP | claimed |
| CN-113960312-B | Serum metabolism marker for diagnosing benign and malignant lung nodules and application thereof | 上海市第一人民医院 | 2025-03-04 | — | — | CN | claimed |
| CN-118150834-A | Application of marker in preparation of product for predicting IgG antibody endurance | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2024-06-07 | — | — | CN | claimed |
| CN-117877567-A | Metabolic marker for clinical early diagnosis of smoke disease and application thereof | 河南省人民医院 | 2024-04-12 | — | — | CN | claimed |
| CN-117321218-A | Regeneration method and kit of reusable initiators for nucleic acid synthesis | 陈呈尧 | 2023-12-29 | — | — | CN | claimed |
| US-20230410977-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES | 2023-12-21 | — | — | US | claimed |
| US-20230390406-A1 | Star Polymer Drug Conjugates | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. | 2023-12-07 | — | — | US | claimed |
| US-20230348903-A1 | OLIGONUCLEOTIDES | Hudson Institute of Medical Research (AU) | 2023-11-02 | — | — | US | claimed |
| EP-4263852-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | Chen, Cheng-Yao (TW) | 2023-10-25 | — | — | EP | claimed |
| EP-1455760-B1 | ULTRAPURE ORAL FLUDARA FORMULATION WITH A FAST RELEASING ACTIVE SUBSTANCE | SCHERING AG (DE) | 2005-09-07 | — | — | EP | claimed |
| CN-1617713-A | Ultrapure oral fludara formulation with a fast releasing active substance | SCHERING AG (DE) | 2005-05-18 | — | — | CN | claimed |
| EP-1455760-A1 | ULTRAPURE ORAL FLUDARA FORMULATION WITH A FAST RELEASING ACTIVE SUBSTANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-15 | — | — | EP | claimed |
| EP-1430145-A2 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) | 2004-06-23 | — | — | EP | claimed |
| US-20040096863-A1 | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-05-20 | — | — | US | claimed |
| US-20030176391-A1 | Oral fludara of high-purity formulation with quick release of active ingredient | SCHERING AG (DE) | 2003-09-18 | — | — | US | claimed |
| WO-2003053418-A1 | ULTRAPURE ORAL FLUDARA FORMULATION WITH A FAST RELEASING ACTIVE SUBSTANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-03 | — | — | WO | claimed |
| US-20030003454-A1 | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer | YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE | 2003-01-02 | — | — | US | claimed |
| WO-2002076280-A2 | METHODS AND KITS FOR DETERMING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2002-10-03 | — | — | WO | claimed |
| US-5352786-A | Di(2-propyl)esters of 1-fluoro-2-phosphonomethoxy-3-P-to-luenesulfonyloxypropanes, their producing and utilization | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1994-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176391-A1 | Oral fludara of high-purity formulation with quick release of active ingredient | CYP2C19, FCGR2A, CYP2C9 | PARP1 4196/4885GDA 771/4885PDPK1 4628/4885 |
| US-20260098287-A1 | METHOD AND KIT FOR REGENERATING REUSABLE INITIATORS FOR NUCLEIC ACID SYNTHESIS | DNMT3L, ADAR, UNG | PARP1 204/4885GDA 113/4885PDPK1 3057/4885 |
| US-20230390406-A1 | Star Polymer Drug Conjugates | CCND3, CCND2, DRD3 | PARP1 380/4885GDA 3610/4885PDPK1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.